89 related articles for article (PubMed ID: 19912990)
21. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Liu GH; Qu J; Suzuki K; Nivet E; Li M; Montserrat N; Yi F; Xu X; Ruiz S; Zhang W; Wagner U; Kim A; Ren B; Li Y; Goebl A; Kim J; Soligalla RD; Dubova I; Thompson J; Yates J; Esteban CR; Sancho-Martinez I; Izpisua Belmonte JC
Nature; 2012 Nov; 491(7425):603-7. PubMed ID: 23075850
[TBL] [Abstract][Full Text] [Related]
22. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
[TBL] [Abstract][Full Text] [Related]
24. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N
Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854
[TBL] [Abstract][Full Text] [Related]
25. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity.
Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W
Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038
[TBL] [Abstract][Full Text] [Related]
26. Clinical heterogeneity of the LRRK2 G2019S mutation.
Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
[TBL] [Abstract][Full Text] [Related]
27. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
[TBL] [Abstract][Full Text] [Related]
28. A trojan horse for Parkinson's disease.
Hu Y; Tong Y
Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
[TBL] [Abstract][Full Text] [Related]
29. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.
Lu CS; Simons EJ; Wu-Chou YH; Fonzo AD; Chang HC; Chen RS; Weng YH; Rohé CF; Breedveld GJ; Hattori N; Gasser T; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2005 Dec; 11(8):521-2. PubMed ID: 16256409
[No Abstract] [Full Text] [Related]
30. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro.
Gloeckner CJ; Schumacher A; Boldt K; Ueffing M
J Neurochem; 2009 May; 109(4):959-68. PubMed ID: 19302196
[TBL] [Abstract][Full Text] [Related]
31. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
Biskup S; West AB
Biochim Biophys Acta; 2009 Jul; 1792(7):625-33. PubMed ID: 18973807
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 interferes with aggresome formation for autophagic clearance.
Bang Y; Kim KS; Seol W; Choi HJ
Mol Cell Neurosci; 2016 Sep; 75():71-80. PubMed ID: 27364102
[TBL] [Abstract][Full Text] [Related]
33. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
Qing H; Wong W; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
[TBL] [Abstract][Full Text] [Related]
34. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
36. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.
Klein CL; Rovelli G; Springer W; Schall C; Gasser T; Kahle PJ
J Neurochem; 2009 Nov; 111(3):703-15. PubMed ID: 19712061
[TBL] [Abstract][Full Text] [Related]
37. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
38. New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2.
Liou GY; Gallo KA
Biochem J; 2009 Oct; 424(1):e1-3. PubMed ID: 19839940
[TBL] [Abstract][Full Text] [Related]
39. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
[TBL] [Abstract][Full Text] [Related]
40. Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson's disease carrying the I2020T mutation in LRRK2.
Ohta E; Sone T; Ukai H; Hisamatsu T; Kitagawa T; Ishikawa M; Nagai M; Ueda HR; Obata F; Okano H
Stem Cell Res; 2020 Dec; 49():102073. PubMed ID: 33181472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
